News | April 27, 2023
Biocon approves NCD issue
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
NGS enables researchers to quickly sequence entire genomes and transcriptomes of organisms.
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Subscribe To Our Newsletter & Stay Updated
